Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.
W. R. Berry
Honoraria - Amgen; Sanofi
M. T. Fleming
No relevant relationships to disclose
T. M. Beer
Research Funding - ImClone Systems
M. A. Kolodziej
No relevant relationships to disclose
S. Awasthi
No relevant relationships to disclose
T. E. Hutson
No relevant relationships to disclose
D. Martincic
No relevant relationships to disclose
Y. Wang
No relevant relationships to disclose
L. Asmar
No relevant relationships to disclose
G. Sonpavde
No relevant relationships to disclose